Question-and-Answer Session
Unidentified Audience Member
[Inaudible Question]
Kevin Bratton
The question is how many physicians have we seen in our efforts right now to launch CAPHOSOL? I am not sure I have an exact number of that. We have gone to a number of shows and attended programs like the Oncology Nursing Society Show earlier this year. And we have a number of promotional marketing materials that have been distributed. I think what’s important to note is the change in the marketing focus that we discussed. I think that if you looked at early in the year, we had four products and the sales force trying to cover four products. And I think that what's important now is changing our focus to use CAPHOSOL as a primary product, and we want to – the sales people to develop their efforts too. We are also becoming much more targeted in terms of which physicians we are going to go after, and so we are paying more effort now to the high decile prescribers of oral mucositis products. So, this is increasing our efforts to speak to medical oncologists, and also we have now started to talk to hematological oncologists. So, the goal really is to start focusing on those doctors that are the high prescribers for oral mucositis type products. Yes.
Unidentified Audience Member
[Inaudible Question]
Kevin Bratton
The question is how much cash we need I guess before we become a self-sustaining company or??
Unidentified Audience Member
[Inaudible Question]
Michael Becker
I am Michael Becker, and I am the President and CEO of Cytogen. Our cash utilization on an annual basis has been a little a bit north of $30 million per year. So, that's been the historical product sales run rate. So the real opportunity to reduce our cash requirements is obviously through the new growth opportunities such as the launch of CAPHOSOL, SOLTAMOX to a smaller extent, and also the expansion of our radio pharmaceutical business. If you look at our P&L right now, you can see that we are at slightly less than a 50% gross margin on the sales that we generate, and again those are historically solely from the radiopharmaceutical business, PROSTASCINT and QUADRAMET. So, we did $17.3 million in sales in 2006 at a – you know let’s just use round numbers at a 50% gross margin. Obviously, we need to generate much more in terms of top line revenue at that gross margin in order to be self-sustainable.
- To read the full transcript on Seeking Alpha, click here »
